Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 8/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30722172 | 1.00 | AAK1 (0.38) | AAK1PDE2AAKT1RORCAKT2 | |
| SCHEMBL30145611 | 0.85 | AKT1 (0.42) | AAK1PDE2AAKT1RORCAKT2 | |
| SCHEMBL18769489 | 0.85 | AKT1 (0.42) | AAK1PDE2AAKT1RORCAKT2 | |
| SCHEMBL30722121 | 0.82 | PDE2A (0.36) | AAK1PDE2AAKT1RORCAKT2 | |
| SCHEMBL26992065 | 0.82 | PDE2A (0.36) | AAK1PDE2AAKT1RORCAKT2 | |
| SCHEMBL28494411 | 0.81 | HDAC1 (0.45) | AAK1AKT1AKT2HDAC3HDAC1 | |
| SCHEMBL2588632 | 0.81 | NPC1 (0.47) | PDE2AAKT1RORCAKT2NPC1 | |
| SCHEMBL1117966 | 0.79 | HDAC3 (0.41) | PDE2ARORCHDAC3HDAC1HDAC2 | |
| SCHEMBL31360210 | 0.79 | CTSB (0.40) | AAK1AKT1AKT2MEN1NPC1 | |
| SCHEMBL2036519 | 0.79 | CTSB (0.40) | AAK1AKT1AKT2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | AAK1 3150/4885PDE2A 3044/4885AKT1 1016/4885 |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | AAK1 3150/4885PDE2A 3044/4885AKT1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.